{"ok":true,"entity":{"id":"gilead-sciences","name":"Gilead Sciences","entityType":"company","officialName":"Gilead Sciences, Inc.","canonicalName":"Gilead Sciences","displayName":"Gilead Sciences","category":"大手バイオ医薬品企業","shortDescription":"1987年創業、米国カリフォルニア州フォスターシティに本社を置くバイオ医薬品企業。抗ウイルス領域、特にHIV治療・予防で世界的な地位を占め、Biktarvyを中核製品とする。近年は長時間作用型のlenacapavir（Yeztugo）によるHIV予防と、Trodelvy等の腫瘍領域への展開を進めている。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.gilead.com","updatedAt":"2026-08-06T01:18:46.240Z","secondaryClusters":[],"alias":["Gilead"],"searchKeywords":["HIV","ウイルス学","腫瘍","Biktarvy"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-06-001","P-01-002"]}